California Institute Awarded Fate Therapeutics $15 Million
The grant supports a clinical trial for an innovative cell therapy treating lupus nephritis patients.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Should public institutions provide financial grants to private companies for pharmaceutical research and development?
The California Institute for Regenerative Medicine has awarded Fate Therapeutics a $15.0 million grant. This funding supports the Phase 2 RECLAIM-LN clinical trial of FT819, an off-the-shelf CAR T cell therapy for patients with severe lupus.
Why it matters
The grant aims to accelerate the development of transformative therapies while addressing significant barriers to patient access for clinical trials. This financial support helps bridge the gap for patients who are refractory to standard immunosuppressive treatments.
The grant funds a trial targeting a subset of the estimated 150,000 U.S. patients living with lupus nephritis. The study aims to enroll approximately 53 patients who have failed at least two prior immunosuppressive therapies.
The players
California Institute for Regenerative Medicine
This state agency oversees grant awards for clinical-stage product candidates that show potential to become transformative medical therapies.
Fate Therapeutics
This biotechnology company focuses on the development of off-the-shelf CAR T cell therapies using induced pluripotent cell technology.
The details
The RECLAIM-LN trial utilizes an open-label, single-arm, multicenter design to evaluate the efficacy of the FT819 therapy. FT819, which carries FDA Regenerative Medicine Advanced Therapy designation, is also part of the FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot program.
Timeline
Week 26 marks the primary endpoint measurement of complete renal response for trial participants.
The Big Picture
The project’s participation in the FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot program illustrates the ongoing regulatory evolution required to bring novel cell therapies to market. This integration marks a departure from traditional drug approval timelines, aiming to standardize manufacturing for complex biological treatments.
This development could eventually expand treatment options for patients suffering from refractory lupus nephritis who currently have limited alternatives. By funding clinical trial access, the grant reduces immediate financial barriers for participants enrolled in the RECLAIM-LN study.
The takeaway
This grant highlights the critical role of state-backed funding in advancing specialized immunotherapy research that large-scale commercial pipelines might otherwise bypass. Patients with refractory conditions are primary beneficiaries of the increased capacity for experimental clinical enrollment.
Further reading
For more news on medical advancements, visit our Biotech section.
Source note: This article includes information reported by Pharmabiz.
Live Poll
Should public institutions provide financial grants to private companies for pharmaceutical research and development?
